Multicenter Study to Evaluate Efficacy, Tolerability, Safety of Derinat

Respiratory Infections in Children Clinical Trial

Official title:

Multicenter Double Blinded Placebo-controlled Randomized Study to Evaluate Clinical Efficacy, Tolerability, Safety of Medical Product Derinat®, Solution for External and Local Use 0.25% in Acute Infections of Respiratory System in Children

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04149431
• Other study ID #: ??-18
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: December 15, 2019
• Est. completion date: May 31, 2022

Study information

• Verified date: October 2019
• Source: PharmPak, LLC
• Contact: Irina Gerasimova, Dr.
• Phone: +79168008485
• Email: gerasimova[@]derinat.ru
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This multicenter prospective double blinded placebo-controlled randomized study is designed to to evaluate clinical efficacy, tolerability and safety of medical product Derinat®, solution for external and local use 0.25% in acute infections of respiratory system in children

Description:

This is a multi-center, double-blind, randomized phase III-IV clinical trial in parallel groups to evaluate the efficacy and safety of Derinat versus Placebo in patients with acute upper respiratory tract infection.

The study will include only patients with mild to moderate acute upper respiratory tract infection, without complications. According to the recommendations of the FDA (Guidance for Industry Influenza: Developing Drugs for Treatment and/or Prophylaxis) this category of patients is the best suited for placebo-controlled studies, because the expected serious risks without treatment are negligible. For studies evaluating the therapy of patients with mild to moderate acute respiratory upper respiratory tract infection without complications, a placebo-controlled trial design is preferred, as opposed to designs with no less efficacy (non-inferiority).

This study provides for the inclusion of both outpatient patients and patients admitted to the hospital for epidemiological indications (i.e. patients with acute respiratory infection of the upper respiratory tract of mild and moderate severity without complications that pose an epidemic risk.

Assessment of criteria of severity of acute respiratory infection of the upper respiratory tract will be carried out by Investigator based on standards of diagnosis and treatment of infectious diseases in children at the stages of medical care, depending on the forms of severity of the disease.

The study is planned sequentially in 5 age groups. The study begins with the older age group and as the results on the safety of the drug are obtained, in the course of the study, it is possible to move to younger age groups

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 350
• Est. completion date: May 31, 2022
• Est. primary completion date: May 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 18 Years

Eligibility

Inclusion Criteria:

1. Signed informed consent

2. Male and female patients.

3. The age of the child at the time of first intranasal administration of drug for age group 1: 12 years to <18 years; for age group 2: from 6 years to <12 years; for age group 3: from 2 years to <6 years; for age group 4: 7 months to <2 years; for age group 5: from 0 months to 6 months.

4. Outpatient and inpatient patients hospitalized for epidemiological reasons, with a diagnosis of acute respiratory infection of the upper respiratory tract of mild to moderate severity. (ICD 10: J00 - J06 Acute respiratory infections of the upper respiratory tract).

5. The positive result of the enzyme immunoassay express test for pathogens of acute respiratory infection of the upper respiratory tract on screening.

6. At least one episode of body temperature up to 38C and above within 48 hours prior to screening.

7. Presence of at least one of the following mild to moderate symptoms at screening:

headache, weakness/malaise, muscle pain/aching, feeling of heat/chills.

8. The duration of the disease is not more than 48 hours at the time of screening according to the patient/parents/adoptive parents.

9. Adequate contraceptive methods during the study for the patients with childbearing potential

Exclusion Criteria:

1. Positive express test (in urine) for pregnancy in patients with childbearing potential (menarche).

2. Individual intolerance or hypersensitivity to any of the components of the drug according to the medical history.

3. Taking any drugs with immunomodulatory effect less than 30 days before screening according to medical history.

4. The presence of complications of acute respiratory infection of the upper respiratory tract, signs of severe disease at the time of screening (fever more than 39ºC, febrile convulsions).

5. Acute infectious diseases: diphtheria, measles, infectious mononucleosis, herpes type 1 and 2, rubella, scarlet fever, acute BGSA-tonsillopharyngitis at the time of screening or 30 days before screening.

6. Chronic diseases of the respiratory system (Bronchial asthma, COPD).

7. HIV infection, chronic viral hepatitis B or C (according to history).

8. Impaired renal function with serum creatinine level more than 1.5 times higher than the upper limit of the normal range.

9. Severe liver failure or active liver disease (including viral hepatitis B or C) and increase of ALT and AST more than 5 times of upper limit of the normal range.

10. Participation in any clinical trials and / or taking an experimental drug within 30 days prior to the screening visit.

11. Other significant diseases and conditions of the patient, including mental and physical diseases

Related Conditions & MeSH terms

• Infection
• Respiratory Infections in Children
• Respiratory Tract Infections

Intervention

Drug:
• Derinat
desoxyribonucleate sodium

Locations

Country	Name	City	State
Russian Federation	Irina Gerasimova	Moscow

Sponsors (1)

Lead Sponsor	Collaborator
PharmPak, LLC

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Superiority of Derinat	Assessment of frequency of resolution of symptoms of acute respiratory infection of the upper respiratory tract confirmed by the absence of symptoms (0 points on the scale of evaluation of symptoms of acute upper respiratory infection during at least 24 hours	through study completion, an average of 30 days
Secondary	Efficacy of Derinat	Assessment of frequency of resolution of symptoms of acute upper respiratory infection? time from start of investigational therapy to resolution of symptoms of acute upper respiratory infection and assessment of frequency of elimination of pathogens of acute respiratory infections of the upper respiratory tract from the mucous membrane of the nasopharynx and oropharynx to Day 8	through study completion, an average of 30 days
Secondary	Safety of Derinat	Assessment of incidence of complications in acute upper respiratory tract infection and the incidence of adverse events and serious adverse events of varying severity according to subjective complaints, laboratory tests, physical examination, assessment of vital signs and electrocardiography	through study completion, an average of 30 days